FDA calendar · August 2018 · built from SEC filings

PDUFA dates August 2018: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in August 2018. The FDA calendar also recorded 6 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in August 2018

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

August 2018: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
August 2, 2018Tigecycline (tigecycline)AMRXFDA approval—ApprovedopenFDA Drugs@FDA
August 7, 2018Orkambi (ivacaftor; lumacaftor)VRTXFDA approval—ApprovedopenFDA Drugs@FDA
August 8, 2018Soluprep S (chlorhexidine gluconate; isopropyl alcohol)SOLVFDA approval—ApprovedopenFDA Drugs@FDA
August 22, 2018Eysuvis (loteprednol etabonate)ALCFDA approval—ApprovedopenFDA Drugs@FDA
August 30, 2018Pifeltro (doravirine)MRKFDA approval—ApprovedopenFDA Drugs@FDA
August 30, 2018Delstrigo (doravirine; lamivudine; tenofovir disoproxil fumarate)MRKFDA approval—ApprovedopenFDA Drugs@FDA

August 2018: dated readouts

No events in this view.

Questions

What PDUFA dates are in August 2018?

0 PDUFA dates fell in August 2018. The FDA calendar also recorded 6 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.